This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ruiz, M. Articles by Bar-Eli, M. Search for Related Content PubMed PubMed Citation Articles by Ruiz, M. Articles by Bar-Eli, M.

Activator Protein 2 Inhibits Tumorigenicity and Represses Vascular Endothelial Growth Factor Transcription in Prostate Cancer Cells

¹ Departments of Cancer Biology,
² Urology, and
³ Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas

Activator protein-2 (AP-2) is a transcription factor that regulates proliferation and differentiation in mammalian cells. We have shown previously that although AP-2 is expressed highly in normal prostatic epithelium, its expression is lost in high-grade prostatic intraepithelial neoplasia and prostate cancer, suggesting that loss of AP-2 plays a role in prostate cancer development. We demonstrate that forced AP-2 expression in the prostate cancer cell line LNCaP-LN3 (AP-2 negative) inhibited dramatically tumor incidence in nude mice. To identify the genes that might have been responsible for this effect, we used microchip expression array. We found several genes known to be involved in malignancy were deregulated, including the vascular endothelial growth factor (VEGF) gene. Because VEGF was down-regulated by 14.7-fold in the AP-2-transfected cells and because it is a major angiogenic factor in prostate cancer development and progression, we chose to examine the AP-2-VEGF interaction. Our evidence suggests that AP-2 repressed transcriptionally the VEGF promoter by competing with the transcriptional activator Sp3. Loss of AP-2 in prostate cancer cells reduced the AP-2:Sp3 ratio and activated VEGF expression. AP-2 acts as a tumor-suppressor gene in prostate cancer. Elucidating the molecular events resulting from loss of AP-2 in the prostate epithelium has implications for the understanding and prevention of the onset of prostate cancer.

This article has been cited by other articles:

				Y. Xu, F. Fang, S. K. Dhar, A. Bosch, W. H. St. Clair, E. J. Kasarskis, and D. K. St. Clair Mutations in the SOD2 Promoter Reveal a Molecular Basis for an Activating Protein 2-Dependent Dysregulation of Manganese Superoxide Dismutase Expression in Cancer Cells Mol. Cancer Res., December 1, 2008; 6(12): 1881 - 1893. [Abstract] [Full Text] [PDF]

				F. Orso, E. Penna, D. Cimino, E. Astanina, F. Maione, D. Valdembri, E. Giraudo, G. Serini, P. Sismondi, M. De Bortoli, et al. AP-2{alpha} and AP-2{gamma} regulate tumor progression via specific genetic programs FASEB J, August 1, 2008; 22(8): 2702 - 2714. [Abstract] [Full Text] [PDF]

				H.-J. Choi, T.-W. Chung, S.-J. Kim, S.-Y. Cho, Y.-S. Lee, Y.-C. Lee, J.-H. Ko, and C.-H. Kim The AP-2{alpha} transcription factor is required for the ganglioside GM3-stimulated transcriptional regulation of a PTEN gene Glycobiology, May 1, 2008; 18(5): 395 - 407. [Abstract] [Full Text] [PDF]

				W.-G. Deng, G. Jayachandran, G. Wu, K. Xu, J. A. Roth, and L. Ji Tumor-specific Activation of Human Telomerase Reverses Transcriptase Promoter Activity by Activating Enhancer-binding Protein-2beta in Human Lung Cancer Cells J. Biol. Chem., September 7, 2007; 282(36): 26460 - 26470. [Abstract] [Full Text] [PDF]

				H. R. Qin, D. Iliopoulos, T. Nakamura, S. Costinean, S. Volinia, T. Druck, J. Sun, H. Okumura, and K. Huebner Wwox Suppresses Prostate Cancer Cell Growth through Modulation of ErbB2-Mediated Androgen Receptor Signaling Mol. Cancer Res., September 1, 2007; 5(9): 957 - 965. [Abstract] [Full Text] [PDF]

				J. A.F. Hannay, J. Liu, Q.-S. Zhu, S. V. Bolshakov, L. Li, P. W.T. Pisters, A. J.F. Lazar, D. Yu, R. E. Pollock, and D. Lev Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation Mol. Cancer Ther., May 1, 2007; 6(5): 1650 - 1660. [Abstract] [Full Text] [PDF]

				A. Lopez-Soto, A. Quinones-Lombrana, R. Lopez-Arbesu, C. Lopez-Larrea, and S. Gonzalez Transcriptional Regulation of ULBP1, a Human Ligand of the NKG2D Receptor J. Biol. Chem., October 13, 2006; 281(41): 30419 - 30430. [Abstract] [Full Text] [PDF]

				N. Wajapeyee, R. Britto, H. M. Ravishankar, and K. Somasundaram Apoptosis Induction by Activator Protein 2{alpha} Involves Transcriptional Repression of Bcl-2 J. Biol. Chem., June 16, 2006; 281(24): 16207 - 16219. [Abstract] [Full Text] [PDF]

				N. Wajapeyee, C. G. Raut, and K. Somasundaram Activator Protein 2{alpha} Status Determines the Chemosensitivity of Cancer Cells: Implications in Cancer Chemotherapy Cancer Res., October 1, 2005; 65(19): 8628 - 8634. [Abstract] [Full Text] [PDF]

				T. Egener, E. Roulet, M. Zehnder, P. Bucher, and N. Mermod Proof of concept for microarray-based detection of DNA-binding oncogenes in cell extracts Nucleic Acids Res., May 12, 2005; 33(8): e79 - e79. [Abstract] [Full Text] [PDF]

				G. Pages and J. Pouyssegur Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors Cardiovasc Res, February 15, 2005; 65(3): 564 - 573. [Abstract] [Full Text] [PDF]

				Z. Salah, M. Maoz, I. Cohen, G. Pizov, D. Pode, M. S. Runge, and R. Bar-Shavit Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression FASEB J, January 1, 2005; 19(1): 62 - 72. [Abstract] [Full Text] [PDF]

				A. B. Heimberger, E. C. McGary, D. Suki, M. Ruiz, H. Wang, G. N. Fuller, and M. Bar-Eli Loss of the AP-2{alpha} Transcription Factor Is Associated with the Grade of Human Gliomas Clin. Cancer Res., January 1, 2005; 11(1): 267 - 272. [Abstract] [Full Text] [PDF]

				M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF]

				J. M. Pellikainen, K. M. Ropponen, V. V. Kataja, J. K. Kellokoski, M. J. Eskelinen, and V.-M. Kosma Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Breast Cancer with a Special Reference to Activator Protein-2, HER2, and Prognosis Clin. Cancer Res., November 15, 2004; 10(22): 7621 - 7628. [Abstract] [Full Text] [PDF]

				Q. Li and R. H. Dashwood Activator Protein 2{alpha} Associates with Adenomatous Polyposis Coli/{beta}-Catenin and Inhibits {beta}-Catenin/T-cell Factor Transcriptional Activity in Colorectal Cancer Cells J. Biol. Chem., October 29, 2004; 279(44): 45669 - 45675. [Abstract] [Full Text] [PDF]